Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates

Core Insights - Alkermes reported quarterly earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.42 per share, but down from $0.73 per share a year ago, representing an earnings surprise of +16.67% [1] - The company achieved revenues of $394.19 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 10.83% and up from $378.14 million year-over-year [2] - Alkermes has outperformed consensus EPS estimates three times in the last four quarters and has also topped revenue estimates three times during the same period [2] Earnings Outlook - The sustainability of Alkermes' stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.49 on revenues of $365.02 million, while the estimate for the current fiscal year is $1.85 on revenues of $1.42 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]